Parkinson’s Disease
Ibogaine and Parkinson’s disease
No trial of ibogaine in Parkinson’s has ever been run. There is no case series and no imaging study. Nobody can tell you whether it helps, and this page exists so that you hear that from us rather than from someone selling you a flight.
The question is a reasonable one. That is the problem.
If ibogaine had nothing to do with dopamine neurons, nobody would ask. It has three genuine points of contact with this disease, and each of them is a rung short of what people take it to mean.
It raises the growth factor this disease is about
Parkinson's is the loss of dopamine neurons in the substantia nigra. In rats, a single dose of ibogaine raises GDNF in exactly that region, and GDNF is the growth factor those neurons depend on.¹⁷
It helps a broken dopamine transporter fold correctly
In cells, ibogaine acts as a molecular chaperone for the dopamine transporter, rescuing misfolded copies caused by a rare inherited disorder that produces parkinsonism in children.⁵⁸ That is a folding disease, not Parkinson's.
The people asking usually arrived through a head injury
Most of the Parkinson's enquiries we get come from people with years of head impacts behind them, and the TBI imaging results are real.⁴² A shared risk factor is not a shared treatment.
The growth factor argument has already been tested. It did not work.
This is the part that usually gets left out. You do not have to speculate about whether raising GDNF helps someone with Parkinson's, because researchers went and did it directly. They implanted delivery ports and infused GDNF itself into the putamen of people with the disease, every four weeks for nine months, against placebo.⁵⁷
The imaging said the drug was working. The people did not get better.
Uptake in the treated tissue rose, which is what you would want to see. The primary clinical endpoint was missed: motor symptoms in the treated group did not improve significantly more than in the placebo group.
An indirect, unmeasured, once-off rise in the same growth factor is not a stronger version of that. If anything it is a weaker one. And the second argument needs the same care: the dopamine transporter work is about a rare inherited fault in how one protein folds, which causes parkinsonism in children. Idiopathic Parkinson’s disease is not a folding disorder. The two share a symptom, not a cause.
That leaves the accounts from public figures. Brett Favre, who attributes his diagnosis to twenty years of head impacts, travelled abroad for ibogaine and described sleeping and feeling better afterward.⁴⁹ We do not dismiss that. We also cannot do anything with it: no scans, no comparison group, and a strong expectation of improvement built into the whole undertaking.
What we will and will not say to you
We will not tell you ibogaine treats Parkinson's disease. Every human efficacy finding for ibogaine in any condition still comes from open-label work, retrospective reviews and case reports, and for this condition there is not even that.⁵⁴ Treating a mechanistic argument as a result is how people end up spending money they do not have on a hope nobody has tested.
Parkinson’s also raises real screening questions rather than theoretical ones. The medication lists are long, and several of the drug classes on them are the ones a physician has to review before ibogaine, either because of heart rhythm or because of how the compound is cleared. Blood pressure regulation is often already unstable in this disease, and ibogaine slows the heart. Those two facts sit next to each other badly enough that some people are told no, and that answer is the screening working.
What we will say is that if you are here because of a head injury history as much as a diagnosis, the TBI research is a different conversation with actual human imaging behind it, and it is worth reading before you decide anything.
Questions people actually ask
Citations (6)
[17] Marton S, González B, Rodríguez-Bottero S, et al. (2019). Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology, 10, 193. Read the source →
Rodent study showing that a single dose of ibogaine raises BDNF expression in the nucleus accumbens, substantia nigra, and prefrontal cortex, and selectively raises GDNF in the ventral tegmental area at the dose range effective in self-administration models.
[42] Cherian K, Keynan J, Anker L, Faerman A, Brown R, Shamma A, Keynan O, Coetzee J, Batail JM, Phillips A, Bassano N, Sahlem G, Inzunza J, Millar T, Dickinson J, Rolle C, Keller J, Adamson M, Kratter I, Williams N (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30, 373–381. Read the source →
The MISTIC trial. 30 male US Special Operations Forces veterans with predominantly mild traumatic brain injury received intravenous magnesium plus oral ibogaine (mean 12.1 mg/kg); 23 met criteria for PTSD at baseline. One month after treatment the group had moved from mild-to-moderate disability to no disability on the WHODAS-2.0 (30.2 to 5.1, d = 2.20), the study primary outcome. PTSD symptoms fell 88% on average, with a 100% response rate and 86% remission (d = 2.54); depression fell 87% (83% remission) and anxiety 81% (83% remission). Suicidal ideation fell from 47% at baseline to 7% at one month. Participants also gained in processing speed, executive function, verbal fluency and verbal learning, with no cognitive decline on any measure, and there were no serious or unexpected treatment-emergent adverse events. Open-label and uncontrolled, in a highly selected cohort, with magnesium co-administered, so the effect cannot be attributed to ibogaine alone.
[49] Yahoo Sports (reporting statements by Brett Favre) (2025). NFL and UFC athletes try 'game-changing' psychedelic to treat brain injury. Yahoo Sports. Read the source →
Brett Favre, who attributes his Parkinson's diagnosis to head impacts sustained across a 20-year NFL career, described travelling abroad for ibogaine and reported a shift in sleep and energy. A public figure account, not clinical evidence, and ibogaine is not an established treatment for Parkinson's.
[54] Esperança MP, Gomes NG, Campos MG (2026). Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders. A Scoping Review. Molecules, 31(3), 545. Read the source →
Scoping review establishing the current tier of human evidence for ibogaine: no randomized, placebo-controlled trial has yet evaluated its efficacy in substance use disorders, and every human efficacy finding to date comes from open-label observational studies, retrospective analyses and case reports. Also covers the cardiac safety profile and the translational work now moving ibogaine into regulated clinical development.
[57] Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, Harrison R, Lewis O, Pritchard G, Howell M, Irving C, Johnson D, Kinch S, Marshall C, Lawrence AD, Blinder S, Sossi V, Stoessl AJ, Skinner P, Mohr E, Gill SS (2019). Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain, 142(3), 512–525. Read the source →
Placebo-controlled trial that delivered GDNF, the growth factor ibogaine is proposed to raise, directly into the putamen of people with Parkinson's disease every four weeks for nine months. Imaging showed the drug was reaching and engaging the tissue, with an increase in putamen 18F-DOPA uptake, but the primary clinical endpoint was not met: motor scores in the treated group did not differ significantly from placebo. The clearest available evidence that raising GDNF in a human brain is not the same as reversing a neurodegenerative disease.
[58] Beerepoot P, Lam VM, Salahpour A (2016). Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells. Journal of Biological Chemistry, 291(42), 22053–22062. Read the source →
Cell study showing that ibogaine can act as a molecular chaperone for the dopamine transporter, helping misfolded copies of the protein fold correctly and reach the cell surface. Rescue was demonstrated for two mutations that cause dopamine transporter deficiency syndrome, a rare inherited condition that produces dystonia and parkinsonism in children. That is a protein-folding disorder, not idiopathic Parkinson's disease, and the work is in cells.
Let’s connect.
No pressure. Tell us a little about what you’re going through.